https://www.businessline.global/lintonpharm-announces-authorization-from-china-health-authority-nmpa-to-proceed-with-a-phase-1-2-trial-evaluating-catumaxomab-for-the-treatment-of-non-muscle-invasive-bladder-cancer/press-release/